New cancer drug trial halted early: what we know

NCT ID NCT06171789

First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 28 times

Summary

This study tested a new drug called PRO1107 in 33 people with advanced solid tumors, including ovarian, endometrial, and lung cancers. The goal was to check safety and see if the drug could shrink tumors. The trial was stopped early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Florida Cancer Specialists

    Sarasota, Florida, 34236, United States

  • HonorHealth Research Institute

    Scottsdale, Arizona, 85258, United States

  • Institution of Hunan Cancer Hospital

    Changsha, Hunan, 410013, China

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • SCRI Oncology Partners

    Nashville, Tennessee, 37203, United States

  • START Mountain Cancer Center

    Salt Lake City, Utah, 78229, United States

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.